Novo Nordisk’s focus on diabetes and obesity shape its business development work, but the company is also exploring other areas. Top Novo Nordisk M&A executive John McDonald discussed his company’s strategy during a session at the BIO conference in San Diego.

The post At BIO, Novo Nordisk’s Top Dealmaker Talks M&A Strategy and What’s Next After GLP-1s appeared first on MedCity News.

By working together to build an ecosystem of support around people with diabetes, the healthcare system as a whole can ensure that no one slips through the cracks.

The post As Interest in GLP-1s Explodes, People Living With Diabetes Need Structured Support To Ensure Effective Use appeared first on MedCity News.

Johns Hopkins Hospital teamed up with Healthy.io, a company that offers smartphone-based technology to improve wound care management for diabetic patients. The partners are conducting a 120-person study to measure the impact of the startup’s technology.

The post Johns Hopkins Is Teaming Up With Healthy.io to Improve Diabetic Patients’ Wound Care appeared first on MedCity News.

Biolinq raked in $58 million in capital this week. The company is developing a wearable patch that uses electrochemical sensors to measure a person’s glucose levels from the intradermal space just beneath the surface of their skin.

The post Biolinq Snags $58M for ‘Smallest Biosensor in the World’ appeared first on MedCity News.

A new report from the Peterson Health Technology Institute analyzed eight digital diabetes management tools. It found that the tools don’t provide meaningful clinical benefits and increase healthcare spending.

The post Report: Digital Diabetes Management Tools Fall Short appeared first on MedCity News.

Valendo Health, the newest startup built at Redesign Health, launched on Tuesday. The company partners with independent endocrinology practices and provides technology to help them thrive in value-based care arrangements.

The post New Startup Launches To Bring VBC to Endocrinology Practices appeared first on MedCity News.

Insulin prices have long been a pain point for diabetics. The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development.

The post Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking appeared first on MedCity News.

New research found that there are no racial disparities in weight loss results among patients taking obesity drugs. However, the study found that people of color have less access to services like behavioral care or surgical interventions, which are often needed in order for patients to lose weight and keep it off. To tackle this issue, Enara Health CEO Rami Bailony argued that the U.S. healthcare system must innovate the way it dispenses weight loss drugs, employing a more holistic care approach.

The post Why One CEO Thinks Drugs Won’t Be Able to Solve the Obesity Crisis appeared first on MedCity News.

Amazon launched a new initiative to help connect people to digital health benefits that they may not know are available to them. Omada Health is its first partner. CEO Sean Duffy said his company stood out from the many other virtual diabetes care companies out there because about 20 million Americans — many of whom shop on Amazon — are eligible for Omada’s programs.

The post Why Omada’s CEO Thinks Amazon Selected His Startup as the 1st Partner for Its New Program appeared first on MedCity News.

Geoff Martha sought to establish a clear line between popular understanding of AI created by apps like ChatGPT and what he believes is the significant impact that Medtronic’s AI-enabled products are already having on patients and other healthcare stakeholders today.

The post Medtronic CEO On the Company’s AI: This Isn’t About ChatGPT appeared first on MedCity News.

Twin Health raked in $50 million in Series D financing. The startup seeks to help patients improve their metabolic health and reduce the need for medications through the “digital twin” technology it sells to employers and health plans.

The post Twin Health Snags $50M to Help Employers, Health Plans Treat Metabolic Disease appeared first on MedCity News.

A new guide from Northeast Business Group on Health helps employers understand the challenges women face when it comes to cardiovascular disease, diabetes and obesity. It also recommends actions that employers can take to support women in their workforce.

The post NEBGH Helps Employers Combat Cardiovascular Disease in Women Through New Guide appeared first on MedCity News.

Roche’s Carmot Therapeutics acquisition brings three clinical-stage assets that the companies say could be best-in-class drugs for metabolic disorders. In addition to standalone use, Roche sees the Carmot molecules as part of potential combinations with its own drug candidates.

The post Roche Lines Up $2.7B Acquisition to Join Chase for New Diabetes, Obesity Drugs appeared first on MedCity News.

The German manufacturing site is the latest capital infrastructure move for Eli Lilly, which has already made $11 billion in investments in its global manufacturing capabilities in the past three years. The new site will help Lilly meet strong demand for its diabetes and obesity drugs.

The post Eli Lilly Plans New $2.5B Manufacturing Site in Germany for Injectable Meds appeared first on MedCity News.

AstraZeneca gains global rights to an oral GLP-1 agonist on track to reach Phase 2 testing in 2024. Under China-based Eccogene, the small molecule’s Phase 1 data show reductions in glucose and body weight.

The post AstraZeneca Pays $185M to Add Oral GLP-1 Drug Candidate to Pipeline appeared first on MedCity News.

Walgreens is seeing “an enormous amount of demand” for injectable weight loss drugs, its president of U.S. healthcare said during the Reuters Total Health conference in Chicago. He declared that the healthcare industry needs to come up with a reimbursement model “that correctly compensates pharmacists and others” to administer these drugs. In his view, reimbursement hasn’t caught up with the demand.

The post Walgreens Exec: Reimbursement Models Need to Catch Up with GLP-1 Demand appeared first on MedCity News.

Eli Lilly weight management drug Zepbound landed its much anticipated FDA approval. The new Lilly product is in the same drug class as Novo Nordisk weight medication Wegovy, but it offers an additional mechanism of action and costs less.

The post FDA Approves Eli Lilly Weight Drug, Now Set to Compete Against Novo’s Wegovy appeared first on MedCity News.

This week, Abbott announced its plans to acquire Bigfoot Biomedical — a startup selling a “smart” insulin pen cap, which collects data from a user’s CGM to help them calculate the right dose. Most analysts were unsurprised to hear of the acquisition given that the two companies have been collaborating for more than six years, but they said the deal reinforces the steady pace of digital innovation in the diabetes care space.

The post Abbott-Bigfoot Deal Proves That Diabetes Is a Hot Area for Digital Health Investment appeared first on MedCity News.

As the U.S. healthcare system works to focus on the move to preventive, personalized care for patients, it’s time to turn the tide on diabetes by addressing the three Cs of chronic disease care: compassion, coordination, and community.

The post Prioritizing SDOH for Patients Living with Chronic Diseases: Compassion, Coordination and Community appeared first on MedCity News.

Amazon Pharmacy announced Tuesday that it is launching automatic coupons for more than 15 insulin and diabetes care brands. The move, while incremental, solves a major pain point for consumers with diabetes, as many struggle to afford insulin products.

The post Amazon’s Automatic Coupons for Diabetes Products While “Incremental” Will Still Be a “Gamechanger,” Experts Say appeared first on MedCity News.

Social media should play a bigger part in public health crisis planning, according to a recent analysis. The analysis explored the crucial role that Twitter and other social media platforms played when the app for Abbott’s FreeStyle Libre system crashed earlier this month in the U.K.

The post Recent Abbott Snafu Shines Spotlight on Social Media’s Role in Public Health Crisis Response appeared first on MedCity News.

Oura — a company selling a ring that tracks peoples’ biometrics — announced new partnerships with three providers of continuous glucose monitors: January, Supersapiens and Veri. These companies will now be receiving sleep scores and other biometric data from Oura so they can see how these measurements affect users’ glucose levels and overall health.

The post Oura Will Now Share Its Sleep Scores With CGM Providers appeared first on MedCity News.

Know Labs recently unveiled the prototype for its non-invasive, portable glucose monitoring device. The device incorporates the company’s proprietary body-radio frequency identification (Bio-RFID) technology — meaning its sensors deploy radio waves that travel through the skin to find and measure molecular signatures in the blood.

The post Meet the Company Building the First-Ever Noninvasive Blood Glucose Monitoring Device appeared first on MedCity News.

With obesity, diabetes, and heart disease rapidly growing among communities of color, we need to do everything we can to help people sustain healthy eating habits. It’ll take more nuance than a Westernized one-size-fits-all diet.

The post Is It Possible To Provide Equitable Nutritional Care for Diabetes and Obesity? appeared first on MedCity News.

Medtronic recently received FDA approval for its MiniMed 780G system, which is an insulin pump that automatically adjusts and corrects type 1 diabetes patients’ glucose levels every five minutes. The news comes two years after Medtronic submitted the system for FDA approval and three years after the company began selling the product in Europe.

The post Medtronic Gains FDA Approval for Newest Insulin Pump appeared first on MedCity News.

Eli Lilly is selling to Amphastar Pharmaceuticals global rights to Baqsimi, an emergency treatment for severe hypoglycemia in diabetes patients. The deal come as Lilly turns its focus to novel medicines for diabetes and other indications.

The post Eli Lilly Unloads Emergency Nasal Spray Diabetes Drug for $500M Up Front appeared first on MedCity News.

Paul Markovich believes in the value of health tech in managing both chronic diseases and in general health and wellness. In this episode, he talks about the company’s Wellvolution platform and the digital tools that are offered there to members, now even to those on Medicaid.

The post MedCity Pivot: Blue Shield of California CEO Says Value of HealthTech Has Been Mixed So Far appeared first on MedCity News.

Novo Nordisk can afford the price cuts prices to several branded and non-branded insulins. Flattening revenue for the pharmaceutical giant’s insulin products is offset by demand for diabetes and obesity drugs from its semaglutide franchise, which continues to grow by leaps and bounds.

The post Novo Nordisk Follows Eli Lilly’s Lead, Lowering Insulin Prices up to 75% appeared first on MedCity News.

Eli Lilly is slashing prices for its insulin products and capping a patient’s monthly out-of-pocket costs at $35. But a financial analyst notes that the company can afford to cut prices on older medicines like insulin because the strategy will help it maintain pricing power for innovative new drugs.

The post Eli Lilly’s Insulin: Cheaper for Patients Without Much Financial Hit to the Firm appeared first on MedCity News.

Virta is available this month to all Blue Shield of California members enrolled in preferred provider organization plans for individual and family, fully insured, self funded and Medicare Advantage. The payer has been working with Virta since 2019 when the digital health company joined Blue Shield of California’s Wellvolution, a platform of digital lifestyle apps.

The post Blue Shield of California Adds Virta Health to Network for Diabetes Care appeared first on MedCity News.